DLA Piper advised Rettig in connection with capital raise for Medix Biochemica

DLA Piper advised Rettig in connection with a capital raise in which ca. EUR 300 million of new investments were raised to DevCo’s single-asset investment vehicle for Medix Biochemica. Medix Biochemica is a leading independent supplier of critical biological raw material products to the in vitro diagnostics (IVD) industry worldwide. Following the capital raise, DevCo’s single-asset investment vehicle for Medix Biochemica has total long-term commitments of EUR 616 million.

The DLA Piper advisory team comprised Jonathan Andersin and Ilkka Liljeroos.